Intervention Review

Drug treatment for myotonia

  1. Jeroen Trip1,*,
  2. Gea G Drost2,
  3. Baziel GM van Engelen3,
  4. C G Faber4

Editorial Group: Cochrane Neuromuscular Disease Group

Published Online: 25 JAN 2006

Assessed as up-to-date: 29 JUL 2009

DOI: 10.1002/14651858.CD004762.pub2


How to Cite

Trip J, Drost GG, van Engelen BGM, Faber CG. Drug treatment for myotonia. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD004762. DOI: 10.1002/14651858.CD004762.pub2.

Author Information

  1. 1

    Diaconessenhuis Meppel, Neurologist, Meppel, Netherlands

  2. 2

    Radboud University Nijmegen Medical Center, Department of Neurophysiology, Nijmegen, Netherlands

  3. 3

    Radboud University Nijmegen Medical Center, Neuromuscular Center Nijmegen, Nijmegen, Netherlands

  4. 4

    MUML, Department Neurology, Maastricht, Netherlands

*Jeroen Trip, Neurologist, Diaconessenhuis Meppel, Hoogeveenseweg 38, Meppel, 7943 KA, Netherlands. jeroentrip1975@gmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 25 JAN 2006

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Mauro Lo Monaco, Adele D’Amico, Marco Luigetti, Jean-François Desaphy, Anna Modoni, Effect of mexiletine on transitory depression of compound motor action potential in recessive myotonia congenita, Clinical Neurophysiology, 2015, 126, 2, 399

    CrossRef

  2. 2
    F. Hanisch, S. Zierz, Therapie-Handbuch Grundwerk inkl 6. Lfg., 2015,

    CrossRef

  3. 3
    Richard T. Moxley, James E. Hilbert, Giovanni Meola, Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease, 2015,

    CrossRef

  4. 4
    Dhiraj Kumar, Rashmi K. Ambasta, Pravir Kumar, Mutational Consequences of Aberrant Ion Channels in Neurological Disorders, The Journal of Membrane Biology, 2014, 247, 11, 1083

    CrossRef

  5. 5
    Charles A. Thornton, Myotonic Dystrophy, Neurologic Clinics, 2014, 32, 3, 705

    CrossRef

  6. 6
    Chad R. Heatwole, Jeffrey M. Statland, Eric L. Logigian, The diagnosis and treatment of myotonic disorders, Muscle & Nerve, 2013, 47, 5
  7. 7
    Jeffrey M. Statland, Yunxia Wang, Rachel Richesson, Brian Bundy, Laura Herbelin, Joe Gomes, Jaya Trivedi, Shannon Venance, Anthony Amato, Michael Hanna, Robert Griggs, Richard J. Barohn, An interactive voice response diary for patients with non-dystrophic myotonia, Muscle & Nerve, 2011, 44, 1
  8. 8
    A. Vela Souto, Canalopatías, Medicine - Programa de Formación Médica Continuada Acreditado, 2011, 10, 78, 5302

    CrossRef

  9. 9
    Diana M. Escolar, Peter O'Carroll, Robert Leshner, Neuromuscular Disorders: Treatment and Management, 2011,

    CrossRef

  10. 10
    Andrew Shao, John N. Hathcock, Risk assessment for the amino acids taurine, l-glutamine and l-arginine, Regulatory Toxicology and Pharmacology, 2008, 50, 3, 376

    CrossRef

  11. 11
    Diana Conte Camerino, Jean-François Desaphy, Domenico Tricarico, Sabata Pierno, Antonella Liantonio, 2008,

    CrossRef

  12. 12
    Christoph Lossin, Alfred L. George, 2008,

    CrossRef

  13. 13
    Ansgar M. Brambrink, Jeffrey R. Kirsch, Perioperative Care of Patients with Neuromuscular Disease and Dysfunction, Anesthesiology Clinics, 2007, 25, 3, 483

    CrossRef